AtomVie Global Radiopharma Partners with ITM for Lutetium-177 Supply Agreement
In a strategic collaboration, AtomVie Global Radiopharma, a leading contract development and manufacturing organization (CDMO) in the radiopharmaceutical sector, has signed a supply agreement with ITM Isotope Technologies Munich SE (ITM), a prominent biotechnology company specializing in medical isotopes. This partnership focuses on enhancing the availability of high-quality Lutetium-177 (n.c.a.) for precision oncology applications.
Bruno Paquin, the CEO of AtomVie, emphasized the critical importance of reliable access to isotopes for companies operating in the radiopharmaceutical industry. He stated, "AtomVie serves various radiopharmaceutical companies that rely on a dependable supply of high-quality radioisotopes. By strengthening our relationship with ITM, a world leader in isotope production, we ensure that both our current and future partners have reliable access to n.c.a. Lutetium-177, thereby supporting the development of advanced therapies and diagnostics programs."
Lutetium-177 (n.c.a.) produced by ITM is meticulously designed to be integrated with targeted molecules, effectively delivering the isotope directly to tumor sites. Once at the targeted location, the high-purity form of Lutetium-177 emits therapeutic beta radiation, which destructively targets cancer cells in a highly localized and precise manner. ITM has registered a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for their n.c.a. Lutetium-177 and holds marketing authorization in the European Union under the brand EndolucinBeta®.
Dr. Andrew Cavey, CEO of ITM, remarked, "We view this agreement with AtomVie—a trusted partner for companies developing novel and innovative radiopharmaceuticals—as a testament to our commitment to servicing the sector through our global production and supply network. Ensuring that our partners have reliable access to high-quality radioisotopes, including Lutetium-177, is a priority for us. Alongside AtomVie and its network of radiopharmaceutical developers, ITM is proud to contribute to expanding the impact of radiopharmaceutical therapy for patients suffering from cancer."
About AtomVie Global Radiopharma
AtomVie Global Radiopharma Inc. stands as a leading global organization dedicated to contract development and manufacturing in the radiopharmaceutical field. Its mission is to propel the development and commercialization of radiopharmaceuticals. AtomVie offers comprehensive solutions, which encompass process and analytical method development, manufacturing under good manufacturing practices (GMP), quality control, regulatory support, and global distribution services for pharmaceuticals intended for clinical or commercial use. They provide valuable support to pharmaceutical and biotechnology companies worldwide that are developing innovative radiation-based therapies and diagnostics. Currently, AtomVie is in the process of launching a state-of-the-art facility in Hamilton, Ontario, spanning 72,300 square feet.
About ITM Isotope Technologies Munich SE
ITM, a leading biopharmaceutical company in the radiopharmaceutical sector, is committed to delivering a new generation of radiopharmaceutical therapies and diagnostics for hard-to-treat tumors. It seeks to meet the needs of oncology patients and healthcare professionals through excellence in the development, production, and global supply of medical radioisotopes. With the patient’s benefit guiding all activities, ITM supports an extensive portfolio of precision oncology projects, including multiple phase 3 trials, combining the company’s high-quality isotopes with various targeted molecules. Leveraging two decades of pioneering experience in radiopharmacy, ITM aims to provide patients with more effective targeted treatments to enhance clinical outcomes and quality of life.
For more information, visit
AtomVie and
ITM.
Media Contacts
For media inquiries related to AtomVie, contact Tina Chainani at +1 905 912 4209 or [email protected].
For ITM corporate communication, reach out to Kathleen Noonan/Julia Westermeir at +49 89 329 8986 1500 or [email protected]. For investor relations, contact Ben Orzelek at +49 89 329 8986 1009 or [email protected].